Biotech Showcase Conference: Notes from the Floor, Day One

Miss the Biotech Showcase conference in San Fransisco? Don't worry, the Investing News Network was there on the floor of the show. Here's a look at day one of the conference.

san-fransisco

At  the first day (January 8) of the Biotech Showcase conference in San Francisco, the Investing News Network (INN) was on the floor of the show to gather insight from industry enthusiasts that discussed various aspects of the healthcare investment world.

Some of the panel discussions and presentations from day one include: a panel discussion on gene therapies, company presentations from industry leaders in the space, a panel discussion on the role of the U.S. Food and Drug Administration, and a  panel of analysts and investors giving predictions for 2018.

If you missed the show–don’t worry. Here INN offers investors a quick look at some of the highlights of the first day.

The promise of gene therapies is beyond exciting and revolutionary, but investors need to be aware that there is still a long way to go for the commercialization of most therapies being worked on. A panel of experts talked on the challenges the industry still faces.

INN attended the company presentation for Eiger Biopharma (NADAQ:EIGR) and Viking Therapeutics (NASDAQ:VKTX) two companies with phase 2 programs getting increasing attention in the public market.

After a daunting summer 2017, Eiger’s share price has been on the rise, with a one year increase of 11.3 percent, whereas Viking has seen an exponential increase of 303.17 percent. On Monday, the company closed the trading day with its shares priced at $5.08 per piece.

At a panel discussing the evolving role of the U.S. Food and Drug Administration (FDA), Dr. Gayatri Gao, outgoing director for the office of orphan drug products development at the regulatory agency, talked about the conversation on a potential abuse of the orphan drug act.

The panel of FDA experts took a closer look at some of the changes brought forth by its new leadership and the potential of change coming directly from the White House.

To close the day, INN covered a panel of analysts and investors on their predictions for the new year. Among the highlights of the panel included the flattering remarks for the mid to small market cap biotech sectors.

John Nolan, managing director with WBB Asset Management said he thinks these smaller companies are the major drivers in the space. The panel also discussed the potential for I/O (immuno oncology) fatigue and the benefits tax reform will have in the business of biotech.

Stay tuned for our additional coverage on the Biotech Showcase conference, where we will post information on the various panels and the work of presenting public companies. Follow us on Twitter at @INN_LifeScience for more photos from the show floor.

Don’t forget to follow us @INN_LifeScience  for real-time news updates.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.

Biotech

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply